The B-cell inhibitory receptor CD22 is a major factor in host resistance to Streptococcus pneumoniae infection.
Animals
B-Lymphocytes
/ immunology
Bacteremia
/ genetics
Female
Host-Pathogen Interactions
Humans
Male
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Inbred CBA
Pneumococcal Infections
/ genetics
Pneumonia, Pneumococcal
/ genetics
Sialic Acid Binding Ig-like Lectin 2
/ deficiency
Streptococcus pneumoniae
/ pathogenicity
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
05
07
2019
accepted:
06
03
2020
entrez:
24
4
2020
pubmed:
24
4
2020
medline:
5
8
2020
Statut:
epublish
Résumé
Streptococcus pneumoniae is a major human pathogen, causing pneumonia and sepsis. Genetic components strongly influence host responses to pneumococcal infections, but the responsible loci are unknown. We have previously identified a locus on mouse chromosome 7 from a susceptible mouse strain, CBA/Ca, to be crucial for pneumococcal infection. Here we identify a responsible gene, Cd22, which carries a point mutation in the CBA/Ca strain, leading to loss of CD22 on B cells. CBA/Ca mice and gene-targeted CD22-deficient mice on a C57BL/6 background are both similarly susceptible to pneumococcal infection, as shown by bacterial replication in the lungs, high bacteremia and early death. After bacterial infections, CD22-deficient mice had strongly reduced B cell populations in the lung, including GM-CSF producing, IgM secreting innate response activator B cells, which are crucial for protection. This study provides striking evidence that CD22 is crucial for protection during invasive pneumococcal disease.
Identifiants
pubmed: 32324805
doi: 10.1371/journal.ppat.1008464
pii: PPATHOGENS-D-19-01231
pmc: PMC7179836
doi:
Substances chimiques
Sialic Acid Binding Ig-like Lectin 2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1008464Subventions
Organisme : Medical Research Council
ID : G0501416
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U142684174
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Exp Med. 2014 Jun 2;211(6):1243-56
pubmed: 24821911
Microbes Infect. 2004 Apr;6(4):377-82
pubmed: 15050965
Science. 2012 Feb 3;335(6068):597-601
pubmed: 22245738
Mamm Genome. 2003 Jul;14(7):448-53
pubmed: 12925893
Science. 1994 Sep 30;265(5181):2037-48
pubmed: 8091226
Immunity. 2016 Nov 15;45(5):963-973
pubmed: 27851925
J Biol Chem. 1996 Apr 19;271(16):9273-80
pubmed: 8621588
J Virol. 2013 Mar;87(6):3361-75
pubmed: 23302871
Infect Immun. 2001 Jan;69(1):426-34
pubmed: 11119534
Glycobiology. 2014 Sep;24(9):807-17
pubmed: 25002414
J Exp Med. 1999 Apr 19;189(8):1307-13
pubmed: 10209047
Eur J Immunol. 2002 Feb;32(2):561-7
pubmed: 11828373
Genes Immun. 2010 Jun;11(4):319-25
pubmed: 19798075
Infect Immun. 2000 Feb;68(2):492-501
pubmed: 10639409
Science. 1996 Nov 1;274(5288):798-801
pubmed: 8864124
Nature. 1996 Dec 19-26;384(6610):634-7
pubmed: 8967951
Nat Rev Immunol. 2011 Jan;11(1):34-46
pubmed: 21151033
Immunity. 2005 Jul;23(1):7-18
pubmed: 16039575
J Immunol. 2010 Apr 1;184(7):3618-27
pubmed: 20200274
Nat Rev Rheumatol. 2014 Jul;10(7):422-8
pubmed: 24763061
PLoS One. 2014 Mar 03;9(3):e89831
pubmed: 24594938
J Immunol. 2018 Mar 1;200(5):1671-1681
pubmed: 29374074
EBioMedicine. 2016 Aug;10:77-84
pubmed: 27432718
Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12402-7
pubmed: 23836650
Vet Rec. 1985 Apr 20;116(16):431-6
pubmed: 3923690
Immunity. 1996 Dec;5(6):551-62
pubmed: 8986715
PLoS One. 2011;6(8):e23413
pubmed: 21858107
Nat Rev Immunol. 2007 Apr;7(4):255-66
pubmed: 17380156
Curr Biol. 1997 Feb 1;7(2):133-43
pubmed: 9016707
J Immunol. 2012 Feb 1;188(3):1075-82
pubmed: 22190185